THE ALIGN-AR EFS TRIAL: JenaValve Pericardial TAVR Aortic Regurgitation Study
A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 100 participants.
Also called NCT02732704
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 100 participants
- Sponsor
- Registry
-
NCT02732704
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- United States, Germany, Netherlands
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT02732704. Allocation not applicable; no masking; primary purpose treatment. Start 2018-04-20 (actual); primary completion 2022-08-29 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- THE ALIGN-AR EFS TRIAL: JenaValve Pericardial TAVR Aortic Regurgitation Study
- Condition
- Aortic Regurgitation
- Intervention (Device)
- JenaValve Pericardial TAVR System
- Lead sponsor
- JenaValve Technology, Inc.
Record details
- Record id
cardio:ct-nct02732704- Content hash
56f97fc2a0b0238d9fd33a7512772d930545d9ca6f40066350af189e84eadd8c